New medication promising to avoid hospitalisations under ‘rapid evaluation’ by EMA

A new treatment for Covid-19, developed by Celltrion, a company in South Korea, is undergoing ‘rapid evaluation’ by EMA – the European Medicines Agency – with a view to approval for use across the bloc. ‘Regdanvimab’ uses a monoclonal antibody which reportedly attaches itself to the ‘spike’ protein of SARS-CoV-2 which causes Covid-19 to develop in certain infected people. The result is a reduced capacity of the virus to enter patients’ cells. Explain reports, EMA’s hope is that this new medication can be given to patients with moderate